MedTrace Logo

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

NCT06398977 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-05-03

No results posted yet for this study

Summary

This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.

Conditions

  • Peritoneal Dialysis Complication
  • Renal Function Aggravated
  • Sodium-glucose Co-transporter-2 Inhibitors

Interventions

DRUG

Dapagliflozin

Dapagliflozin10MG, PO once daily

Sponsors & Collaborators

  • Sichuan Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Jin Chen, MD · Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06398977 on ClinicalTrials.gov